Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 88 entries
Sorted by: Best Match Show Resources per page
67. Fixed-effect and random-effects models.

JPEN. Journal of parenteral and enteral nutrition

Koretz RL.
PMID: 34859890
JPEN J Parenter Enteral Nutr. 2021 Dec 03; doi: 10.1002/jpen.2312. Epub 2021 Dec 03.

No abstract available.

Cite
Koretz RL. 67. Fixed-effect and random-effects models. JPEN J Parenter Enteral Nutr. 2021;doi: 10.1002/jpen.2312.
Koretz, R. L. (2021). 67. Fixed-effect and random-effects models. JPEN. Journal of parenteral and enteral nutrition, . https://doi.org/10.1002/jpen.2312
Koretz, Ronald L. "67. Fixed-effect and random-effects models." JPEN. Journal of parenteral and enteral nutrition vol. (2021). doi: https://doi.org/10.1002/jpen.2312
Koretz RL. 67. Fixed-effect and random-effects models. JPEN J Parenter Enteral Nutr. 2021 Dec 03; doi: 10.1002/jpen.2312. Epub 2021 Dec 03. PMID: 34859890.
Copy Download .nbib Format: NLM
Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein.

The AAPS journal

Bajaj R, Chong LB, Zou L, Tsakalozou E, Ni Z, Giacomini KM, Kroetz DL.
PMID: 34528148
AAPS J. 2021 Sep 15;23(5):106. doi: 10.1208/s12248-021-00631-8.

P-glycoprotein (P-gp) plays a critical role in drug oral bioavailability, and modulation of this transporter can alter the safety and/or efficacy profile of substrate drugs. Individual oral molecular excipients that inhibit P-gp function have been considered a mechanism for...

Cite
Bajaj R, Chong LB, Zou L, et al. Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein. AAPS J. 2021;23(5):106doi: 10.1208/s12248-021-00631-8.
Bajaj, R., Chong, L. B., Zou, L., Tsakalozou, E., Ni, Z., Giacomini, K. M., & Kroetz, D. L. (2021). Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein. The AAPS journal, 23(5), 106. https://doi.org/10.1208/s12248-021-00631-8
Bajaj, Ruchika, et al. "Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein." The AAPS journal vol. 23,5 (2021): 106. doi: https://doi.org/10.1208/s12248-021-00631-8
Bajaj R, Chong LB, Zou L, Tsakalozou E, Ni Z, Giacomini KM, Kroetz DL. Interaction of Commonly Used Oral Molecular Excipients with P-glycoprotein. AAPS J. 2021 Sep 15;23(5):106. doi: 10.1208/s12248-021-00631-8. PMID: 34528148.
Copy Download .nbib Format: NLM
Conceptualizing ecosystem services using social-ecological networks.

Trends in ecology & evolution

Felipe-Lucia MR, Guerrero AM, Alexander SM, Ashander J, Baggio JA, Barnes ML, Bodin Ö, Bonn A, Fortin MJ, Friedman RS, Gephart JA, Helmstedt KJ, Keyes AA, Kroetz K, Massol F, Pocock MJO, Sayles J, Thompson RM, Wood SA, Dee LE.
PMID: 34969536
Trends Ecol Evol. 2021 Dec 27; doi: 10.1016/j.tree.2021.11.012. Epub 2021 Dec 27.

Social-ecological networks (SENs) represent the complex relationships between ecological and social systems and are a useful tool for analyzing and managing ecosystem services. However, mainstreaming the application of SENs in ecosystem service research has been hindered by a lack...

Cite
Felipe-Lucia MR, Guerrero AM, Alexander SM, et al. Conceptualizing ecosystem services using social-ecological networks. Trends Ecol Evol. 2021;doi: 10.1016/j.tree.2021.11.012.
Felipe-Lucia, M. R., Guerrero, A. M., Alexander, S. M., Ashander, J., Baggio, J. A., Barnes, M. L., Bodin, �. �., Bonn, A., Fortin, M. J., Friedman, R. S., Gephart, J. A., Helmstedt, K. J., Keyes, A. A., Kroetz, K., Massol, F., Pocock, M. J. O., Sayles, J., Thompson, R. M., Wood, S. A., & Dee, L. E. (2021). Conceptualizing ecosystem services using social-ecological networks. Trends in ecology & evolution, . https://doi.org/10.1016/j.tree.2021.11.012
Felipe-Lucia, María R, et al. "Conceptualizing ecosystem services using social-ecological networks." Trends in ecology & evolution vol. (2021). doi: https://doi.org/10.1016/j.tree.2021.11.012
Felipe-Lucia MR, Guerrero AM, Alexander SM, Ashander J, Baggio JA, Barnes ML, Bodin Ö, Bonn A, Fortin MJ, Friedman RS, Gephart JA, Helmstedt KJ, Keyes AA, Kroetz K, Massol F, Pocock MJO, Sayles J, Thompson RM, Wood SA, Dee LE. Conceptualizing ecosystem services using social-ecological networks. Trends Ecol Evol. 2021 Dec 27; doi: 10.1016/j.tree.2021.11.012. Epub 2021 Dec 27. PMID: 34969536.
Copy Download .nbib Format: NLM
GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.

Clinical and translational science

Ferracini AC, Lopes-Aguiar L, Lourenço GJ, Yoshida A, Lima CSP, Sarian LO, Derchain S, Kroetz DL, Mazzola PG.
PMID: 33326171
Clin Transl Sci. 2021 Mar;14(2):720-728. doi: 10.1111/cts.12937. Epub 2020 Dec 16.

Variation in drug disposition genes might contribute to susceptibility to toxicities and interindividual differences in clinical management on chemotherapy for epithelial ovarian cancer (EOC). This study was designed to explore the association of GST and ABCB1 genetic variation with...

Cite
Ferracini AC, Lopes-Aguiar L, Lourenço GJ, et al. GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer. Clin Transl Sci. 2020;14(2):720-728doi: 10.1111/cts.12937.
Ferracini, A. C., Lopes-Aguiar, L., Lourenço, G. J., Yoshida, A., Lima, C. S. P., Sarian, L. O., Derchain, S., Kroetz, D. L., & Mazzola, P. G. (2021). GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer. Clinical and translational science, 14(2), 720-728. https://doi.org/10.1111/cts.12937
Ferracini, Amanda Canato, et al. "GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer." Clinical and translational science vol. 14,2 (2021): 720-728. doi: https://doi.org/10.1111/cts.12937
Ferracini AC, Lopes-Aguiar L, Lourenço GJ, Yoshida A, Lima CSP, Sarian LO, Derchain S, Kroetz DL, Mazzola PG. GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer. Clin Transl Sci. 2021 Mar;14(2):720-728. doi: 10.1111/cts.12937. Epub 2020 Dec 16. PMID: 33326171; PMCID: PMC7993324.
Copy Download .nbib Format: NLM
Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers.

Cell death and differentiation

Montinaro A, Areso Zubiaur I, Saggau J, Kretz AL, Ferreira RMM, Hassan O, Kitzig E, Müller I, El-Bahrawy MA, von Karstedt S, Kulms D, Liccardi G, Lemke J, Walczak H.
PMID: 34535764
Cell Death Differ. 2021 Sep 17; doi: 10.1038/s41418-021-00869-x. Epub 2021 Sep 17.

Primary or acquired therapy resistance is a major obstacle to the effective treatment of cancer. Resistance to apoptosis has long been thought to contribute to therapy resistance. We show here that recombinant TRAIL and CDK9 inhibition cooperate in killing...

Cite
Montinaro A, Areso Zubiaur I, Saggau J, et al. Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers. Cell Death Differ. 2021;doi: 10.1038/s41418-021-00869-x.
Montinaro, A., Areso Zubiaur, I., Saggau, J., Kretz, A. L., Ferreira, R. M. M., Hassan, O., Kitzig, E., Müller, I., El-Bahrawy, M. A., von Karstedt, S., Kulms, D., Liccardi, G., Lemke, J., & Walczak, H. (2021). Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers. Cell death and differentiation, . https://doi.org/10.1038/s41418-021-00869-x
Montinaro, Antonella, et al. "Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers." Cell death and differentiation vol. (2021). doi: https://doi.org/10.1038/s41418-021-00869-x
Montinaro A, Areso Zubiaur I, Saggau J, Kretz AL, Ferreira RMM, Hassan O, Kitzig E, Müller I, El-Bahrawy MA, von Karstedt S, Kulms D, Liccardi G, Lemke J, Walczak H. Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers. Cell Death Differ. 2021 Sep 17; doi: 10.1038/s41418-021-00869-x. Epub 2021 Sep 17. PMID: 34535764.
Copy Download .nbib Format: NLM
Update in gastroenterology and hepatology.

Annals of internal medicine

Koretz RL, Lipman TO.
PMID: 16144893
Ann Intern Med. 2005 Sep 06;143(5):347-54. doi: 10.7326/0003-4819-143-5-200509060-00010.

No abstract available.

Cite
Koretz RL, Lipman TO. Update in gastroenterology and hepatology. Ann Intern Med. 2005;143(5):347-54doi: 10.7326/0003-4819-143-5-200509060-00010.
Koretz, R. L., & Lipman, T. O. (2005). Update in gastroenterology and hepatology. Annals of internal medicine, 143(5), 347-54. https://doi.org/10.7326/0003-4819-143-5-200509060-00010
Koretz, Ronald L, and Lipman, Timothy O. "Update in gastroenterology and hepatology." Annals of internal medicine vol. 143,5 (2005): 347-54. doi: https://doi.org/10.7326/0003-4819-143-5-200509060-00010
Koretz RL, Lipman TO. Update in gastroenterology and hepatology. Ann Intern Med. 2005 Sep 06;143(5):347-54. doi: 10.7326/0003-4819-143-5-200509060-00010. PMID: 16144893.
Copy Download .nbib Format: NLM
Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections.

ACP journal club

Koretz RL.
PMID: 15656551
ACP J Club. 2005 Jan-Feb;142(1):10-1.

No abstract available.

Cite
Koretz RL. Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections. ACP J Club. 2005;142(1):10-1
Koretz, R. L. (2005). Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections. ACP journal club, 142(1), 10-1.
Koretz, Ronald L. "Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections." ACP journal club vol. 142,1 (2005): 10-1.
Koretz RL. Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections. ACP J Club. 2005 Jan-Feb;142(1):10-1. PMID: 15656551.
Copy Download .nbib Format: NLM
Snack time.

Gastroenterology

Koretz RL.
PMID: 16890626
Gastroenterology. 2006 Aug;131(2):678-9. doi: 10.1053/j.gastro.2006.04.063.

No abstract available.

Cite
Koretz RL. Snack time. Gastroenterology. 2006;131(2):678-9doi: 10.1053/j.gastro.2006.04.063.
Koretz, R. L. (2006). Snack time. Gastroenterology, 131(2), 678-9. https://doi.org/10.1053/j.gastro.2006.04.063
Koretz, Ronald L. "Snack time." Gastroenterology vol. 131,2 (2006): 678-9. doi: https://doi.org/10.1053/j.gastro.2006.04.063
Koretz RL. Snack time. Gastroenterology. 2006 Aug;131(2):678-9. doi: 10.1053/j.gastro.2006.04.063. PMID: 16890626.
Copy Download .nbib Format: NLM
Mechanistic insights into the pathogenesis of microtubule-targeting agent-induced peripheral neuropathy from pharmacogenetic and functional studies.

Basic & clinical pharmacology & toxicology

Chua KC, El-Haj N, Priotti J, Kroetz DL.
PMID: 34481421
Basic Clin Pharmacol Toxicol. 2022 Jan;130:60-74. doi: 10.1111/bcpt.13654. Epub 2021 Oct 02.

Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity that affects 30%-40% of patients undergoing cancer treatment. Although multiple mechanisms of chemotherapy-induced neurotoxicity have been described in preclinical models, these have not been translated into widely effective strategies for...

Cite
Chua KC, El-Haj N, Priotti J, et al. Mechanistic insights into the pathogenesis of microtubule-targeting agent-induced peripheral neuropathy from pharmacogenetic and functional studies. Basic Clin Pharmacol Toxicol. 2021;130:60-74doi: 10.1111/bcpt.13654.
Chua, K. C., El-Haj, N., Priotti, J., & Kroetz, D. L. (2022). Mechanistic insights into the pathogenesis of microtubule-targeting agent-induced peripheral neuropathy from pharmacogenetic and functional studies. Basic & clinical pharmacology & toxicology, 13060-74. https://doi.org/10.1111/bcpt.13654
Chua, Katherina C, et al. "Mechanistic insights into the pathogenesis of microtubule-targeting agent-induced peripheral neuropathy from pharmacogenetic and functional studies." Basic & clinical pharmacology & toxicology vol. 130 (2022): 60-74. doi: https://doi.org/10.1111/bcpt.13654
Chua KC, El-Haj N, Priotti J, Kroetz DL. Mechanistic insights into the pathogenesis of microtubule-targeting agent-induced peripheral neuropathy from pharmacogenetic and functional studies. Basic Clin Pharmacol Toxicol. 2022 Jan;130:60-74. doi: 10.1111/bcpt.13654. Epub 2021 Oct 02. PMID: 34481421; PMCID: PMC8716520.
Copy Download .nbib Format: NLM
JPEN Journal Club 64. Incorrect statistics.

JPEN. Journal of parenteral and enteral nutrition

Koretz RL.
PMID: 34346081
JPEN J Parenter Enteral Nutr. 2021 Aug 04; doi: 10.1002/jpen.2245. Epub 2021 Aug 04.

No abstract available.

Cite
Koretz RL. JPEN Journal Club 64. Incorrect statistics. JPEN J Parenter Enteral Nutr. 2021;doi: 10.1002/jpen.2245.
Koretz, R. L. (2021). JPEN Journal Club 64. Incorrect statistics. JPEN. Journal of parenteral and enteral nutrition, . https://doi.org/10.1002/jpen.2245
Koretz, Ronald L. "JPEN Journal Club 64. Incorrect statistics." JPEN. Journal of parenteral and enteral nutrition vol. (2021). doi: https://doi.org/10.1002/jpen.2245
Koretz RL. JPEN Journal Club 64. Incorrect statistics. JPEN J Parenter Enteral Nutr. 2021 Aug 04; doi: 10.1002/jpen.2245. Epub 2021 Aug 04. PMID: 34346081.
Copy Download .nbib Format: NLM
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.

British journal of cancer

Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F.
PMID: 34853435
Br J Cancer. 2021 Dec 01; doi: 10.1038/s41416-021-01617-1. Epub 2021 Dec 01.

No abstract available.

Cite
Quintanilha JCF, Wang J, Sibley AB, et al. Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2021;doi: 10.1038/s41416-021-01617-1.
Quintanilha, J. C. F., Wang, J., Sibley, A. B., Jiang, C., Etheridge, A. S., Shen, F., Jiang, G., Mulkey, F., Patel, J. N., Hertz, D. L., Dees, E. C., McLeod, H. L., Bertagnolli, M., Rugo, H., Kindler, H. L., Kelly, W. K., Ratain, M. J., Kroetz, D. L., Owzar, K., Schneider, B. P., Lin, D., & Innocenti, F. (2021). Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. British journal of cancer, . https://doi.org/10.1038/s41416-021-01617-1
Quintanilha, Julia C F, et al. "Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients." British journal of cancer vol. (2021). doi: https://doi.org/10.1038/s41416-021-01617-1
Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2021 Dec 01; doi: 10.1038/s41416-021-01617-1. Epub 2021 Dec 01. PMID: 34853435.
Copy Download .nbib Format: NLM
Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.

British journal of cancer

Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F.
PMID: 34853435
Br J Cancer. 2022 Jan;126(1):162. doi: 10.1038/s41416-021-01617-1.

No abstract available.

Cite
Quintanilha JCF, Wang J, Sibley AB, et al. Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022;126(1):162doi: 10.1038/s41416-021-01617-1.
Quintanilha, J. C. F., Wang, J., Sibley, A. B., Jiang, C., Etheridge, A. S., Shen, F., Jiang, G., Mulkey, F., Patel, J. N., Hertz, D. L., Dees, E. C., McLeod, H. L., Bertagnolli, M., Rugo, H., Kindler, H. L., Kelly, W. K., Ratain, M. J., Kroetz, D. L., Owzar, K., Schneider, B. P., Lin, D., & Innocenti, F. (2022). Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. British journal of cancer, 126(1), 162. https://doi.org/10.1038/s41416-021-01617-1
Quintanilha, Julia C F, et al. "Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients." British journal of cancer vol. 126,1 (2022): 162. doi: https://doi.org/10.1038/s41416-021-01617-1
Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, Dees EC, McLeod HL, Bertagnolli M, Rugo H, Kindler HL, Kelly WK, Ratain MJ, Kroetz DL, Owzar K, Schneider BP, Lin D, Innocenti F. Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022 Jan;126(1):162. doi: 10.1038/s41416-021-01617-1. PMID: 34853435.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 88 entries